Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes.

Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P.

Diabetes Obes Metab. 2011 Apr;13(4):366-73. doi: 10.1111/j.1463-1326.2011.01362.x.

PMID:
21226820
2.

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach.

Xu L, Man CD, Charbonnel B, Meninger G, Davies MJ, Williams-Herman D, Cobelli C, Stein PP.

Diabetes Obes Metab. 2008 Dec;10(12):1212-20. doi: 10.1111/j.1463-1326.2008.00887.x. Epub 2008 May 12.

PMID:
18476982
3.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group.

Diabetes Obes Metab. 2007 Sep;9(5):733-45. Epub 2007 Jun 26.

PMID:
17593236
4.

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.

Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T.

Diabetes Obes Metab. 2010 Apr;12(4):323-33. doi: 10.1111/j.1463-1326.2009.01167.x.

PMID:
20380653
5.

[Incretin strategy in the treatment of type 2 diabetes mellitus--the DPP-IV inhibitor sitagliptin].

Perusicová J.

Vnitr Lek. 2007 Oct;53(10):1109-13. Review. Czech.

PMID:
18072437
6.

Effects of sitagliptin on 24-h glycemic changes in Japanese patients with type 2 diabetes assessed using continuous glucose monitoring.

Mori Y, Taniguchi Y, Matsuura K, Sezaki K, Yokoyama J, Utsunomiya K.

Diabetes Technol Ther. 2011 Jul;13(7):699-703. doi: 10.1089/dia.2011.0025. Epub 2011 Apr 19.

PMID:
21504334
7.

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes.

Ogawa S, Ishiki M, Nako K, Okamura M, Senda M, Mori T, Ito S.

Tohoku J Exp Med. 2011;223(2):133-5.

8.

Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus.

Zerilli T, Pyon EY.

Clin Ther. 2007 Dec;29(12):2614-34. doi: 10.1016/j.clinthera.2007.12.034. Review.

PMID:
18201579
9.

Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes.

Öz Ö, Kıyıcı S, Ersoy C, Cander S, Yorulmaz H, Gül CB, Ünal OK, Sarandol E, Kırhan E, Sığırlı D, Ertürk E, Tuncel E, Imamoğlu S.

Diabetes Res Clin Pract. 2011 Nov;94(2):212-6. doi: 10.1016/j.diabres.2011.07.031. Epub 2011 Aug 19.

PMID:
21855160
10.

[New drugs; exenatide and sitagliptin].

van Bronswijk H, Dubois EA, Pijl H, Cohen AF.

Ned Tijdschr Geneeskd. 2008 Apr 12;152(15):876-9. Review. Dutch.

PMID:
18512528
11.

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes.

Davidson JA, Parente EB, Gross JL.

Arq Bras Endocrinol Metabol. 2008 Aug;52(6):1039-49. Review.

13.
14.

Effect of sitagliptin on post-prandial glucagon and GLP-1 levels in patients with type 1 diabetes: investigator-initiated, double-blind, randomized, placebo-controlled trial.

Garg SK, Moser EG, Bode BW, Klaff LJ, Hiatt WR, Beatson C, Snell-Bergeon JK.

Endocr Pract. 2013 Jan-Feb;19(1):19-28. doi: 10.4158/EP12100.OR.

PMID:
23186950
15.
16.

Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea.

Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD.

Diabetes Res Clin Pract. 2009 Jan;83(1):106-16. doi: 10.1016/j.diabres.2008.10.009. Epub 2008 Dec 20.

PMID:
19097665
17.

Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement.

Alba M, Sheng D, Guan Y, Williams-Herman D, Larson P, Sachs JR, Thornberry N, Herman G, Kaufman KD, Goldstein BJ.

Curr Med Res Opin. 2009 Oct;25(10):2507-14. doi: 10.1185/03007990903209514.

PMID:
19691426
18.

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus.

Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I.

Diabetes Metab Res Rev. 2010 Oct;26(7):540-9. doi: 10.1002/dmrr.1114.

PMID:
20824678
19.

Effects of miglitol versus sitagliptin on postprandial glucose and lipoprotein metabolism in patients with type 2 diabetes mellitus.

Okada K, Yagyu H, Kotani K, Yamazaki H, Ozaki K, Takahashi M, Nagashima S, Osuga J, Ishibashi S.

Endocr J. 2013;60(7):913-22. Epub 2013 Apr 10.

20.

Treatment of HNF1-alpha MODY with the DPP-4 inhibitor Sitagliptin(1).

Lumb AN, Gallen IW.

Diabet Med. 2009 Feb;26(2):189-90. doi: 10.1111/j.1464-5491.2008.02645.x. No abstract available.

PMID:
19236626
Items per page

Supplemental Content

Write to the Help Desk